search
Back to results

L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia (L-Arg)

Primary Purpose

Pre-Eclampsia

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
L-arginine supplementation in a medical food
Vitamin C and E supplementation in a medical food
Sponsored by
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pre-Eclampsia focused on measuring Pre-Eclampsia, Hypertension,pregnancy-induced, Preterm labor

Eligibility Criteria

19 Years - 32 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Previous pregnancy complicated with pre-eclampsia/eclampsia
  • Singleton pregnancy
  • Gestational age >20 weeks <34 weeks
  • Protein excretion < 300 mg/day

Exclusion Criteria:

  • Multiple gestation
  • Major fetal anomaly
  • Pre-existing hypertension
  • Pre-existing renal disease
  • Diabetes
  • Collagen vascular disease
  • Cancer or strong family history of cancer in first degree relatives
  • Preexisting maternal disease requiring medication

Sites / Locations

  • Univesity of Pennsylvania
  • Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes

Outcomes

Primary Outcome Measures

Development of preeclampsia

Secondary Outcome Measures

Development of eclampsia
Occurrence of HELP syndrome
Occurrence of preterm labor, preterm premature rupture of the membranes
Gestational age at delivery

Full Information

First Posted
May 4, 2007
Last Updated
May 7, 2007
Sponsor
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
Collaborators
University of Pennsylvania, Bill and Melinda Gates Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00469846
Brief Title
L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia
Acronym
L-Arg
Official Title
Supplementation With L-Arginine and Antioxidant Vitamins During Pregnancy in a Medical Food to Reduce the Risk of Preeclampsia in a High Risk Population
Study Type
Interventional

2. Study Status

Record Verification Date
April 2007
Overall Recruitment Status
Terminated
Why Stopped
Recruitment and follow-up has been completed.
Study Start Date
January 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
Collaborators
University of Pennsylvania, Bill and Melinda Gates Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is intended to assess the efficacy of L-arginine supplementation with antioxidant vitamins delivered in a medical food in reducing the incidence of preeclampsia in a high-risk population.
Detailed Description
Preeclampsia is a syndrome of unknown origin characterized by hypertension, edema and proteinuria. It usually appears in the third trimester and occurs most frequently in primigravidas. Preeclampsia may be complicated by life-threatening conditions including seizures, severe hepatic dysfunction, renal failure and coagulopathy; it is one of the leading causes of maternal morbidity and mortality worldwide. Preeclampsia is cited as the leading cause of maternal death in surveys of maternal mortality in Mexico (25% of maternal deaths). Specific Aim 1. To assess the efficacy of L-arginine supplementation with antioxidant vitamins delivered in a medical food in reducing the incidence of preeclampsia in a high-risk population. Two other groups will receive the food (bars) either with antioxidant vitamins alone or without vitamins in order to test the impact of vitamin supplements on prevention of preeclampsia. The primary hypothesis to be tested is that supplemental L-arginine in combination with antioxidant vitamins will significantly reduce preeclampsia (hypertension and proteinuria) and its complications in a high-risk population (women whose blood pressure is > 140/90 after 20 weeks gestation without proteinuria). Secondary hypotheses to be tested include that antioxidant vitamin supplementation contributes to the reduction in preeclampsia; that supplemental L-arginine and antioxidant vitamins will improve neonatal outcomes (reduced incidence of prematurity and intrauterine growth retardation); that preeclampsia is correlated inversely with plasma L-arginine levels, directly with the plasma levels of the endogenous NO synthase inhibitor, asymmetric dimethyl arginine (ADMA), and inversely with urinary NO metabolites, a marker of endogenous NO production; and that preeclampsia is inversely correlated with maternal plasma levels of antioxidant vitamins.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pre-Eclampsia
Keywords
Pre-Eclampsia, Hypertension,pregnancy-induced, Preterm labor

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
585 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
L-arginine supplementation in a medical food
Intervention Type
Procedure
Intervention Name(s)
Vitamin C and E supplementation in a medical food
Primary Outcome Measure Information:
Title
Development of preeclampsia
Time Frame
During pregnancy
Secondary Outcome Measure Information:
Title
Development of eclampsia
Time Frame
During pregnancy
Title
Occurrence of HELP syndrome
Time Frame
During pregnancy
Title
Occurrence of preterm labor, preterm premature rupture of the membranes
Time Frame
During pregnancy
Title
Gestational age at delivery
Time Frame
End of pregnancy

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
32 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Previous pregnancy complicated with pre-eclampsia/eclampsia Singleton pregnancy Gestational age >20 weeks <34 weeks Protein excretion < 300 mg/day Exclusion Criteria: Multiple gestation Major fetal anomaly Pre-existing hypertension Pre-existing renal disease Diabetes Collagen vascular disease Cancer or strong family history of cancer in first degree relatives Preexisting maternal disease requiring medication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Felipe Vadillo-Ortega, M.D.,Ph.D.
Organizational Affiliation
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
Official's Role
Principal Investigator
Facility Information:
Facility Name
Univesity of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104-6142
Country
United States
Facility Name
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
City
Mexico City
State/Province
D.f.
ZIP/Postal Code
11000
Country
Mexico

12. IPD Sharing Statement

Citations:
PubMed Identifier
21596735
Citation
Vadillo-Ortega F, Perichart-Perera O, Espino S, Avila-Vergara MA, Ibarra I, Ahued R, Godines M, Parry S, Macones G, Strauss JF. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ. 2011 May 19;342:d2901. doi: 10.1136/bmj.d2901.
Results Reference
derived

Learn more about this trial

L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia

We'll reach out to this number within 24 hrs